Cargando…
Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data
Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of Plasmodium vivax, including dormant liver stages – so called hypnozoites. Its long half-life of ~15 days is allowing for a single exposure regimen. It has been under development since 1980 and received approval b...
Autores principales: | Hounkpatin, Aurore B, Kreidenweiss, Andrea, Held, Jana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411314/ https://www.ncbi.nlm.nih.gov/pubmed/30881061 http://dx.doi.org/10.2147/IDR.S151031 |
Ejemplares similares
-
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
por: Rajapakse, Senaka, et al.
Publicado: (2015) -
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019) -
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
por: Lacerda, M.V.G., et al.
Publicado: (2019) -
Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
por: Ebstie, Yehenew A, et al.
Publicado: (2016) -
Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India?
por: Ahmad, Sundus Shafat, et al.
Publicado: (2021)